Intensity Therapeutics
INTS
9 hedge funds and large institutions have $1.19M invested in Intensity Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
599% more capital invested
Capital invested by funds: $170K → $1.19M (+$1.02M)
350% more funds holding
Funds holding: 2 → 9 (+7)
0.09% more ownership
Funds ownership: 0% → 0.09% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
Hohimer Wealth Management
Seattle,
Washington
|
+$1.03M |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$266K |
| 3 |
Millennium Management
New York
|
+$137K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$128K |
| 5 |
BlackRock
New York
|
+$56.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$169K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HWM
1
Hohimer Wealth Management
Seattle,
Washington
| $740K | +$1.03M | +7,459 | New |
|
|
SPC
2
Sigma Planning Corp
Ann Arbor,
Michigan
| $191K | +$266K | +1,926 | New |
|
|
3
Millennium Management
New York
| $101K | +$137K | +993 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $94.2K | +$128K | +923 | New |
|
|
5
BlackRock
New York
| $40.6K | +$56.6K | +410 | New |
|
6
Wells Fargo
San Francisco,
California
| $9.85K | +$13.7K | +99 | New |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $7.94K | +$11.1K | +80 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $4.29K | +$5.66K | +41 | New |
|
|
GWS
9
Glassman Wealth Services
Vienna,
Virginia
| $794 | – | – | – |
|
10
JP Morgan Chase
New York
| $4 | – | – | – |
|
|
11
Walleye Capital
New York
| – | -$169K | -1,135 | Closed |
|
INTS Hedge Fund Activity: Q3 2023 in Review
9 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q3 2023, worth a combined $1.19M — up 599% from $170K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new INTS positions and 1 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hohimer Wealth Management, opening a new position worth an estimated $1.03M. The largest seller was Walleye Capital, exiting entirely with an estimated $169K sold.
- 9 institutional investors held Intensity Therapeutics (INTS) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $1.19M of Intensity Therapeutics stock for Q3 2023, up 599% quarter-over-quarter.
- 8 funds opened new Intensity Therapeutics positions in Q3 2023 and 1 closed out, a net change of +7 holders.
- The largest Intensity Therapeutics buyer in Q3 2023 was Hohimer Wealth Management, an estimated $1.03M added.
- The largest Intensity Therapeutics seller in Q3 2023 was Walleye Capital, an estimated $169K sold.
Based on aggregated 13F filings for Q3 2023.